戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1               None of the neonates developed nephrogenic systemic fibrosis.
2 ystemic fibrosis and ectopic ossification in nephrogenic systemic fibrosis.
3 ts with severe renal dysfunction at risk for nephrogenic systemic fibrosis.
4 ical and pathologic findings consistent with nephrogenic systemic fibrosis.
5  of a sometimes fatal condition in patients, nephrogenic systemic fibrosis.
6 plays a critical role in the pathogenesis of nephrogenic systemic fibrosis.
7 , cases were analyzed for the development of nephrogenic systemic fibrosis.
8                                              Nephrogenic systemic fibrosis, also known as nephrogenic
9 e recent association of this lanthanide with nephrogenic systemic fibrosis, an untreatable disease, h
10 ction, but there is also a risk of producing nephrogenic systemic fibrosis and cerebral deposits of u
11 imuli may participate in the pathogenesis of nephrogenic systemic fibrosis and of other fibrotic diso
12     Clinical reports support the evidence of nephrogenic systemic fibrosis as a systemic disease and
13 Med database was searched by using the term "Nephrogenic systemic fibrosis" from January 2000 to Febr
14  Gd(3+) and potential side effects including nephrogenic systemic fibrosis have led to the search for
15 dolinium-based contrast agents are linked to nephrogenic systemic fibrosis in patients with renal ins
16 lain their causal role in the development of nephrogenic systemic fibrosis in renally impaired patien
17 n Gadoxetic acid may be safe with respect to nephrogenic systemic fibrosis in this patient population
18                                              Nephrogenic systemic fibrosis is a new disorder reported
19                             The pathology of nephrogenic systemic fibrosis is characterized by abnorm
20                        Clinical awareness of nephrogenic systemic fibrosis is still emerging and futu
21 g that gadoxetate disodium does not incite a nephrogenic systemic fibrosis-like fibrotic change in th
22                          Background Although nephrogenic systemic fibrosis (NSF) affects the use of g
23                                 The risk for nephrogenic systemic fibrosis (NSF) after exposure to ne
24 st agents for hypersensitivity reactions and nephrogenic systemic fibrosis (NSF) but had lower confid
25                       Background The risk of nephrogenic systemic fibrosis (NSF) following administra
26                                  The risk of nephrogenic systemic fibrosis (NSF) from group II GBCM i
27  bodies were thought to be pathognomonic for nephrogenic systemic fibrosis (NSF) in the setting of ch
28                                              Nephrogenic systemic fibrosis (NSF) is a fibrosing skin
29                                              Nephrogenic systemic fibrosis (NSF) is a rapidly progres
30                                              Nephrogenic systemic fibrosis (NSF) is a severe fibrosin
31                                              Nephrogenic systemic fibrosis (NSF) is associated with g
32 icates that there are limited data regarding nephrogenic systemic fibrosis (NSF) risk, but there are
33 m patients with systemic sclerosis (SSc) and nephrogenic systemic fibrosis (NSF) was performed to ide
34 sented as a novel means for the diagnosis of nephrogenic systemic fibrosis (NSF), a rare disease occu
35  disease, have been strongly associated with nephrogenic systemic fibrosis (NSF), a severe systemic f
36 ew data in 13 patients with biopsy-confirmed nephrogenic systemic fibrosis (NSF), assess the associat
37 e a small risk of adverse effects, including nephrogenic systemic fibrosis (NSF), the untreatable con
38 mpaired kidney function and the incidence of nephrogenic systemic fibrosis (NSF).
39 eir product labeling to describe the risk of nephrogenic systemic fibrosis (NSF).
40 connective tissue or skin disease resembling nephrogenic systemic fibrosis (NSF-like) and a broader s
41 o uniformly effective interventions to treat nephrogenic systemic fibrosis other than successful rena
42 lls in the fibrotic and calcified tissues of nephrogenic systemic fibrosis patients.
43                    While a specific cause of nephrogenic systemic fibrosis remains to be established,
44 pe and function relevant to the pathology of nephrogenic systemic fibrosis using immunofluorescence,
45  We also examined tissues from patients with nephrogenic systemic fibrosis, using IHC to identify the
46 udies are scant; therefore, a mouse model of nephrogenic systemic fibrosis was established.
47 ased contrast agents in patients at risk for nephrogenic systemic fibrosis was recently shown to avoi
48 cts) and from lesional skin of patients with nephrogenic systemic fibrosis were exposed to a range of
49                                  No cases of nephrogenic systemic fibrosis were noted.
50  Although 639 patients with biopsy-confirmed nephrogenic systemic fibrosis were reported, only seven